Mineralys Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Mineralys Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Mineralys Therapeutics, Inc. made a loss over the last year. Mineralys Therapeutics, Inc. owes $0.18 for every $1 it owns. Mineralys Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossMineralys Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
3.45The share price is 3.45 times Mineralys Therapeutics, Inc.'s book value per share, higher than 60% of Healthcare companies in United States.
Market cap
$1.9 BThe total market value of all of Mineralys Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 74% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$551 MWhat Mineralys Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$6.23Net worth divided by the number of shares. The share price of $21.47 is 3.4 times this, which is the P/B above.
Return on equity (ROE)
-80.9%Mineralys Therapeutics, Inc. lost 80.9% of its shareholders' money over the last year, lower than 66% of Healthcare companies in United States.
Owes vs Owns
0.18×Mineralys Therapeutics, Inc. owes $0.18 for every $1 it owns (low), lower than 77% of Healthcare companies in United States.
Dividend yield
NoneMineralys Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossMineralys Therapeutics, Inc. made a loss in each of the last two years.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Mineralys Therapeutics, Inc.: $1.9 B ÷ $551 M (30 Jun 2026) = 3.4.
What is Mineralys Therapeutics, Inc.'s return on equity?
Mineralys Therapeutics, Inc. lost 80.9% of its shareholders' money over the last year, lower than 66% of Healthcare companies in United States.
How much does Mineralys Therapeutics, Inc. owe compared with what it owns?
Mineralys Therapeutics, Inc. owes $0.18 for every $1 it owns (low), lower than 77% of Healthcare companies in United States.
Does Mineralys Therapeutics, Inc. pay a dividend?
No. Mineralys Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.